Today on Drug Discovery & Development
How is coronavirus vaccine development going in the U.S.?
Thermo Fisher Scientific analytical platform could accelerate trace elements analysis
Drug Discovery and Development See More >
How Brookhaven National Laboratory is fighting COVID-19
Deciphering the key characteristics of the virus that causes COVID-19 and using experiments and computational methods to identify promising drug and vaccine candidates — those are but some of the efforts underway at the U.S. Department of Energy’s Brookhaven National Laboratory in Upton, N.Y. The laboratory is also exploring options to help supply medical professionals…
Genomics/Proteomics See More >
SGI-DNA touts its automated gene printer for coronavirus vaccine development
Synthetic biology company SGI-DNA is touting its efforts to accelerate research in the creation of vaccines for SARS-CoV-2, the virus causing the COVID-19 pandemic. The San Diego-based company said in a news release last month that it built the genes thought to be critical to developing successful vaccines against the virus and made those tools…
Infectious Disease See More >
How is coronavirus vaccine development going in the U.S.?
Researchers in Pittsburgh and Boston are moving forward with research into two separate vaccine programs against SARS-CoV-2, the new coronavirus causing the COVID-19 pandemic. The work of the University of Pittsburgh School of Medicine researchers is detailed in a paper published recently in EBioMedicine, which is published by the Lancet. Delivery of the vaccine involved…
Oncology See More >
CEL-SCI prices $5.5m common stock offering
Phase 3 cancer immunotherapy company Cel-Sci (NYSE:CVM) announced today that it priced an underwritten public offering of common stock with expected gross proceeds of $5.5 million. Vienna, Va.–based Cel-Sci is offering 606,395 shares of common stock at a price of $9.07 per share to total the $5.5 million before deducting underwriting discounts and other estimated expenses. The…
